

Sequential Maternal Screening, Part 1, Serum

Test ID: SEQA

Explanation:

Mayo Clinic Laboratories (MCL) has been notified by the Perinatal Quality Foundation (PQF) that their Nuchal Translucency Quality Review (NTQR) program will end on December 15, 2023. This will impact the MCL process for sonographer qualification for submission of NT measurements for the First Trimester Maternal Screen (1STT1) and the Sequential Maternal Screen, Part 1 (SEQA).

After the end of the NTQR program on December 15, 2023, MCL will honor NTQR certification for sonographers through December 31, 2024. After this time, we recommend previously NTQR certified sonographers become certified through the Fetal Medicine Foundation (FMF) to continue to submit NT measurements as part of First Trimester Screening and Sequential Maternal Screening through Mayo Clinic Laboratories. A link to the FMF USA's website is provided here: http://www.fetalmedicineusa.com/accreditation.php

For questions regarding the closure of the NTQR Program, please email directly to the Perinatal Quality Foundation at support@perinatalquality.org.

Questions

Contact Bethany Feind, Laboratory Resource Coordinator at 800-533-1710.